Allogeneic Hematopoietic Stem Cell Transplantation Cohort Study
1 other identifier
observational
3,000
1 country
3
Brief Summary
Clinical observational studies using epidemiologic theories and methods. Through the collection of various clinically relevant data, specific outcomes are evaluated in hematologic transplant patients, providing high quality real-world data for clinical practice, informing public health decision-making, and reducing the burden of disease
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2021
Longer than P75 for all trials
3 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2021
CompletedFirst Submitted
Initial submission to the registry
November 13, 2024
CompletedFirst Posted
Study publicly available on registry
November 27, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2031
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2031
November 27, 2024
November 1, 2024
10.7 years
November 13, 2024
November 24, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Overall Survival (OS)
OS since enrollment
Time Frame: through study completion, an average of 5 year
Secondary Outcomes (7)
Strictly complete remission (sCR)
Time Frame: through study completion, an average of 5 year
Complete remission (CR)
Time Frame: through study completion, an average of 5 year
Very Good Partial Relief (VGPR)
Time Frame: through study completion, an average of 5 year
Partial remission (PR)
Time Frame: through study completion, an average of 5 year
Minor Relief (MR)
Time Frame: through study completion, an average of 5 year
- +2 more secondary outcomes
Study Arms (1)
Cohort 1
Patients who are proposed to undergo or have undergone allogeneic hematopoietic stem cell transplantation at the Stem Cell Transplant Center and Post-Transplant Medical Consortium at Regent Hospital
Eligibility Criteria
Patients who are proposed to undergo or have undergone allogeneic hematopoietic stem cell transplantation
You may qualify if:
- At least one visit to a stem cell transplant center beginning January 1, 2021
- Proposed to undergo or have undergone hematopoietic stem cell transplantation
You may not qualify if:
- Long-term follow-up information for patients not available for any reason (e.g., unavailable or with serious concomitant disease) according to investigator opinion
- Due to alcohol and drug addiction thus affecting their ability to follow the requirements of the study
- Presence of conditions that could jeopardize patient safety or affect their adherence to the protocol, according to the investigator's opinion
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Ruijin Hospitallead
Study Sites (3)
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China
Shanghai Liquan Hospital
Shanghai, China
Shanghai Zhaxin Hospital
Shanghai, China
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- OTHER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Director of the Center for Translational Medicine
Study Record Dates
First Submitted
November 13, 2024
First Posted
November 27, 2024
Study Start
May 1, 2021
Primary Completion (Estimated)
December 31, 2031
Study Completion (Estimated)
December 31, 2031
Last Updated
November 27, 2024
Record last verified: 2024-11
Data Sharing
- IPD Sharing
- Will not share